NEXTGEN BIOMED LTD |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 101.8 ILa | 0.00% |
|
0.00% | -19.97% |
| 2023 | Nextgen Biomed Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| 2023 | Nextgen Biomed Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 | CI |
Valuation
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8.524 | 8.495 | 7.683 | 79.61 | 60.47 | 27.18 |
| Enterprise Value (EV) 1 | 4.237 | 5.449 | 5.783 | 73.92 | 48.51 | 21.94 |
| P/E ratio | -5.65 x | -6.72 x | -6.33 x | -54.5 x | -21.7 x | -3.17 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | -2.76 x | -4.5 x | -4.66 x | -55.7 x | -17.1 x | -6.14 x |
| EV / FCF | -3.91 x | -7.13 x | -8.19 x | -228 x | -17 x | -16 x |
| FCF Yield | -25.6% | -14% | -12.2% | -0.44% | -5.89% | -6.25% |
| Price to Book | 2.27 x | 3.42 x | 6.05 x | 11.4 x | 2.91 x | 2.2 x |
| Nbr of stocks (in thousands) | 4,832 | 4,832 | 4,832 | 5,528 | 7,224 | 7,225 |
| Reference price 2 | 1.764 | 1.758 | 1.590 | 14.40 | 8.370 | 3.762 |
| Announcement Date | 29/03/18 | 28/03/19 | 18/03/20 | 31/03/21 | 31/03/22 | 03/02/23 |
1ILS in Million2ILS
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -1.536 | -1.21 | -1.24 | -1.327 | -2.833 | -3.574 |
| EBIT 1 | -1.538 | -1.211 | -1.241 | -1.328 | -2.837 | -3.581 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -1.506 | -1.27 | -1.216 | -1.298 | -2.548 | -8.58 |
| Net income 1 | -1.499 | -1.264 | -1.214 | -1.296 | -2.55 | -8.572 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.3120 | -0.2616 | -0.2512 | -0.2640 | -0.3856 | -1.186 |
| Free Cash Flow 1 | -1.083 | -0.7648 | -0.7062 | -0.3246 | -2.856 | -1.372 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 29/03/18 | 28/03/19 | 18/03/20 | 31/03/21 | 31/03/22 | 03/02/23 |
1ILS in Million2ILS
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 4.29 | 3.05 | 1.9 | 5.69 | 12 | 5.24 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -1.08 | -0.76 | -0.71 | -0.32 | -2.86 | -1.37 |
| ROE (net income / shareholders' equity) | -34.3% | -42% | -68.3% | -32.3% | -18.5% | -52.2% |
| ROA (Net income/ Total Assets) | -18.6% | -20.3% | -30.7% | -16.2% | -11.1% | -11.6% |
| Assets 1 | 8.062 | 6.237 | 3.953 | 8.005 | 22.97 | 73.76 |
| Book Value Per Share 2 | 0.7800 | 0.5100 | 0.2600 | 1.260 | 2.880 | 1.710 |
| Cash Flow per Share 2 | 0.8900 | 0.6300 | 0.3900 | 1.030 | 1.660 | 0.7300 |
| Capex | - | - | - | 0.01 | - | - |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 29/03/18 | 28/03/19 | 18/03/20 | 31/03/21 | 31/03/22 | 03/02/23 |
1ILS in Million2ILS
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -19.97% | 2.21M | |
| +9.38% | 27.43B | |
| -29.70% | 3.18B | |
| -16.08% | 2.53B | |
| +19.05% | 2.49B | |
| +11.11% | 2.16B | |
| -4.24% | 2.03B | |
| +5.56% | 1.61B | |
| +3.25% | 1.31B | |
| +29.73% | 1.29B |
- Stock Market
- Equities
- NXGN Stock
- Financials Nextgen Biomed Ltd
